The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
Open accessAbstract
Cyclin-dependent kinases (CDKs) are serine/threonine kinases whose catalytic activities are regulated by interactions with cyclins and CDK inhibitors (CKIs). CDKs are key regulatory enzymes involved in cell proliferation through regulating cell-cycle checkpoints and transcriptional events in response to extracellular and intracellular signals. Not surprisingly, the dysregulation of CDKs is a hallmark of cancers, and inhibition of specific members is considered an attractive target in cancer therapy. In breast cancer (BC), dual CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, combined with other agents, were approved by the Food and Drug Administration (FDA) recently for the treatment of hormone receptor positive (HR+) advanced or metastatic breast cancer (A/MBC), as well as other sub-types of breast cancer. Furthermore, ongoing studies identified more selective CDK inhibitors as promising clinical targets. In this review, we focus on the roles of CDKs in driving cell-cycle progression, cell-cycle checkpoints, and transcriptional regulation, a highlight of dysregulated CDK activation in BC. We also discuss the most relevant CDK inhibitors currently in clinical BC trials, with special emphasis on CDK4/6 inhibitors used for the treatment of estrogen receptor-positive (ER+)/human epidermal growth factor 2-negative (HER2−) M/ABC patients, as well as more emerging precise therapeutic strategies, such as combination therapies and microRNA (miRNA) therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Malumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Lim, S., & Kaldis, P. (2013) · Development · doi:10.1242/dev.091744 · Cited by 1,487
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Controlling the elongation phase of transcription with P-TEFb
Peterlin, B. M., & Price, D. H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.014 · Cited by 1,144
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Cdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1
Zhao, H., & Piwnica-Worms, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4129-4139.2001 · Cited by 1,091 · cited 2×
“The checkpoint kinases phosphatidylinositol 3-kinase (PI3K)-like protein kinases (PI3KKs) ataxia telangiectasia and Rad3-related (ATR) or ataxia telangiectasia mutated (ATM) protein, and the transducer checkpoint kinases CHK1 (encoded by the CHEK1 gene) and CHK2 (encoded by the CHEK2 gene) are key regulators of DNA da…”
BackgroundAn integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Overall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
The Mediator complex: a central integrator of transcription
Allen, B. L., & Taatjes, D. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3951 · Cited by 922
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911149 · Cited by 865
Progressive Activation of CyclinB1-Cdk1 Coordinates Entry to Mitosis
Gavet, O., & Pines, J. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.02.013 · Cited by 844
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro
Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., & Elledge, S. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190030497 · Cited by 829
The molecular biology of spindle assembly checkpoint signaling dynamics.
Musacchio, A. (2015) · Current Biology · doi:10.1016/j.cub.2015.08.051 · Cited by 778 · cited 1×
“In order to establish and maintain the mitotic checkpoint, the TTK recruits many checkpoint proteins to kinetochores during mitosis via phosphorylating its substrates to ensure adequate chromosome segregation and genomic integrity [33,34].”
BackgroundThe Spindle Assembly Checkpoint
Lara-Gonzalez, P., Westhorpe, F. G., & Taylor, S. S. (2012) · Current Biology · doi:10.1016/j.cub.2012.10.006 · Cited by 773
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-018-0097-z · Cited by 685
Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication
Okuda, M., Horn, H. F., Tarapore, P., Tokuyama, Y., Smulian, A. G., Chan, P.-K., Knudsen, E. S., Hofmann, I. A., Snyder, J. D., Bove, K. E., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00093-3 · Cited by 685
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., Freed, E., Ligon, A. H., Vena, N., Ogino, S., et al. (2008) · Nature · doi:10.1038/nature07179 · Cited by 672
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011) · Genes & Development · doi:10.1101/gad.16962311 · Cited by 522
Ubiquitin ligases in oncogenic transformation and cancer therapy
Senft, D., Qi, J., & Ronai, Z. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.105 · Cited by 489
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B. J., Lee, T. I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.063 · Cited by 465
Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle.
Watanabe, N., Broome, M., & Hunter, T. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07180.x · Cited by 450
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0300 · Cited by 444
Cyclin D1 in Breast Cancer Pathogenesis
Arnold, A., & Papanikolaou, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.064 · Cited by 411
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II
Larochelle, S., Amat, R., Glover-Cutter, K., Sansó, M., Zhang, C., Allen, J. J., Shokat, K. M., Bentley, D. L., & Fisher, R. P. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2399 · Cited by 390
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Horiuchi, D., Kusdra, L., Huskey, N. E., Chandriani, S., Lenburg, M. E., Gonzalez-Angulo, A. M., Creasman, K. J., Bazarov, A. V., Smyth, J. W., Davis, S. E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111512 · Cited by 378
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Ma, T., Van Tine, B. A., Wei, Y., Garrett, M. D., Nelson, D., Adams, P. D., Wang, J., Qin, J., Chow, L. T., & Harper, J. W. (2000) · Genes & Development · doi:10.1101/gad.829500 · Cited by 372
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366
HIF1A Employs CDK8-Mediator to Stimulate RNAPII Elongation in Response to Hypoxia
Galbraith, M. D., Allen, M. A., Bensard, C. L., Wang, X., Schwinn, M. K., Qin, B., Long, H. W., Daniels, D. L., Hahn, W. C., Dowell, R. D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.048 · Cited by 359
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
Quereda, V., Bayle, S., Vena, F., Frydman, S. M., Monastyrskyi, A., Roush, W. R., & Duckett, D. R. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.004 · Cited by 352
Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1248 · Cited by 317
Cyclin C/Cdk3 Promotes Rb-Dependent G0 Exit
Ren, S., & Rollins, B. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00300-9 · Cited by 316
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
Dorand, R. D., Nthale, J., Myers, J. T., Barkauskas, D. S., Avril, S., Chirieleison, S. M., Pareek, T. K., Abbott, D. W., Stearns, D. S., Letterio, J. J., et al. (2016) · Science · doi:10.1126/science.aae0477 · Cited by 315
Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., Gelbert, L. M., Shannon, H. E., Sanchez-Martinez, C., & De Dios, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062745 · Cited by 284
Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
Sedlacek, H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.6.1143 · Cited by 275
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Asghar, U. S., Barr, A. R., Cutts, R., Beaney, M., Babina, I., Sampath, D., Giltnane, J., Lacap, J. A., Crocker, L., Young, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0369 · Cited by 268
Benson, C., White, J., Bono, J. D., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603509 · Cited by 261
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Spatiotemporal regulation of the anaphase-promoting complex in mitosis
Sivakumar, S., & Gorbsky, G. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3934 · Cited by 259
The CDK inhibitors in cancer research and therapy
Cicenas, J., & Valius, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1039-4 · Cited by 243
Iorns, E., Turner, N. C., Elliott, R., Syed, N., Garrone, O., Gasco, M., Tutt, A. N. J., Crook, T., Lord, C. J., & Ashworth, A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.001 · Cited by 230
Hurvitz, S. A., Martin, M., Press, M. F., Chan, D., Fernandez-Abad, M., Petru, E., Rostorfer, R., Guarneri, V., Huang, C.-S., Barriga, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1425 · Cited by 227
The Mediator complex: a master coordinator of transcription and cell lineage development
Yin, J.-W., & Wang, G. (2014) · Development · doi:10.1242/dev.098392 · Cited by 222
Lin, T. S., Ruppert, A. S., Johnson, A. J., Fischer, B., Heerema, N. A., Andritsos, L. A., Blum, K. A., Flynn, J. M., Jones, J. A., Hu, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6944 · Cited by 222
Cdk1-Dependent Regulation of the Mitotic Inhibitor Wee1
Harvey, S. L., Charlet, A., Haas, W., Gygi, S. P., & Kellogg, D. R. (2005) · Cell · doi:10.1016/j.cell.2005.05.029 · Cited by 208
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib
Kwapisz, D. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4385-3 · Cited by 202
Whittaker, S. R., Walton, M. I., Garrett, M. D., & Workman, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0110 · Cited by 195
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
Sánchez-Martínez, C., Lallena, M. J., Sanfeliciano, S. G., & de Dios, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126637 · Cited by 194
Liang, K., Gao, X., Gilmore, J. M., Florens, L., Washburn, M. P., Smith, E., & Shilatifard, A. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01426-14 · Cited by 192
Emerging links between CDK cell cycle regulators and Wnt signaling
Davidson, G., & Niehrs, C. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.05.002 · Cited by 185
Targeting the cell cycle in breast cancer: towards the next phase
Thu, K., Soria-Bretones, I., Mak, T., & Cescon, D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1502567 · Cited by 185
Spring, L. M., Zangardi, M. L., Moy, B., & Bardia, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0142 · Cited by 178
Michaloglou, C., Crafter, C., Siersbaek, R., Delpuech, O., Curwen, J. O., Carnevalli, L. S., Staniszewska, A. D., Polanska, U. M., Cheraghchi-Bashi, A., Lawson, M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0537 · Cited by 177
Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
Koniaras, K., Cuddihy, A. R., Christopoulos, H., Hogg, A., & O'Connell, M. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204942 · Cited by 176
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Sobhani, N., D’Angelo, A., Pittacolo, M., Roviello, G., Miccoli, A., Corona, S. P., Bernocchi, O., Generali, D., & Otto, T. (2019) · Cells · doi:10.3390/cells8040321 · Cited by 167
Ding, L., Gu, H., Xiong, X., Ao, H., Cao, J., Lin, W.-S., Yu, M., Lin, J., & Cui, Q. (2019) · Cells · doi:10.3390/cells8121492 · Cited by 165
Self-citationPhylogenetic analysis of CDK and cyclin proteins in premetazoan lineages
Cao, L., Chen, F., Yang, X., Xu, W., Xie, J., & Yu, L. (2014) · BMC Evolutionary Biology · doi:10.1186/1471-2148-14-10 · Cited by 163
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Tien, J. F., Mazloomian, A., Cheng, S.-W. G., Hughes, C. S., Chow, C. C. T., Canapi, L. T., Oloumi, A., Trigo-Gonzalez, G., Bashashati, A., Xu, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx187 · Cited by 163
Cyclin dependent kinases in cancer: Potential for therapeutic intervention
Canavese, M., Santo, L., & Raje, N. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.19589 · Cited by 159
Mita, M. M., Joy, A. A., Mita, A. C., Sankhala, K. K., Jou, Y., Zhang, D., Statkevich, P., Zhu, Y., Yao, S., Small, K. A., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.016 · Cited by 156
The Role of Cdk5 in Neuroendocrine Thyroid Cancer
Pozo, K., Castro‐Rivera, E., Tan, C., Plattner, F., Schwach, G., Siegl, V., Meyer, D. A., Guo, A., Gundara, J. S., Mettlach, G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.027 · Cited by 156
Self-citationInsights into APC/C: from cellular function to diseases and therapeutics
Zhou, Z., He, M., Shah, A. A., & Wan, Y. (2016) · Cell Division · doi:10.1186/s13008-016-0021-6 · Cited by 154
Ou, C.-Y., Poon, V. Y., Maeder, C. I., Watanabe, S., Lehrman, E. K., Fu, A. K. Y., Park, M., Fu, W., Jørgensen, E. M., Ip, N. Y., et al. (2010) · Cell · doi:10.1016/j.cell.2010.04.011 · Cited by 151
The RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain
Jerónimo, C., Collin, P., & Robert, F. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.02.006 · Cited by 151
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers
Santo, L., Siu, K. T., & Raje, N. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.024 · Cited by 142
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
Curigliano, G., Pardo, P. G., Meric‐Bernstam, F., Conte, P., Lolkema, M. P., Beck, J. T., Bardia, A., Martinez‐García, M., Penault-Llorca, F. M., Dhuria, S. V., et al. (2016) · The Breast · doi:10.1016/j.breast.2016.06.008 · Cited by 135
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Kettner, N. M., Vijayaraghavan, S., Durak, M. G., Bui, T. N., Kohansal, M., Ha, M. J., Liu, B., Rao, X., Wang, J., Yi, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3274 · Cited by 135
High cyclin B1 expression is associated with poor survival in breast cancer
Aaltonen, K., Amini, R., Heikkilä, P., Aittomäki, K., Tamminen, A., Nevanlinna, H. A., & BLOMQVIST, C. P. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604874 · Cited by 134
Characterization of Cyclin L1 and L2 Interactions with CDK11 and Splicing Factors
Loyer, P., Trembley, J. H., Grenet, J. A., Busson, A., Corlu, A., Zhao, W., Koçak, M., Kidd, V. J., & Lahti, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708188200 · Cited by 133
Cyclin K goes with Cdk12 and Cdk13
Kohoutek, J., & Blažek, D. (2012) · Cell Division · doi:10.1186/1747-1028-7-12 · Cited by 131
The Writers, Readers, and Functions of the RNA Polymerase II C-Terminal Domain Code
Jerónimo, C., Bataille, A. R., & Robert, F. (2013) · Chemical Reviews · doi:10.1021/cr4001397 · Cited by 130
CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression
Liang, Q. Y., Li, L., Zhang, J., Yang, L., Wang, L., Liu, D., Feng, J., Hou, P., Yao, R., Zhang, Y., et al. (2013) · Scientific Reports · doi:10.1038/srep02932 · Cited by 127
Viladevall, L., Amour, C. V. S., Rosebrock, A. P., Schneider, S., Zhang, C., Allen, J. J., Shokat, K. M., Schwer, B., Leatherwood, J., & Fisher, R. P. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.01.029 · Cited by 120
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
Barroso‐Sousa, R., Shapiro, G. I., & Tolaney, S. M. (2016) · Breast Care · doi:10.1159/000447284 · Cited by 119
The CDK Network: Linking Cycles of Cell Division and Gene Expression
Fisher, R. P. (2012) · Genes & Cancer · doi:10.1177/1947601912473308 · Cited by 118
The Dual Role of MicroRNAs in Colorectal Cancer Progression
Ding, L., Lan, Z., Xiong, X., Ao, H., Feng, Y., Gu, H., Yu, M., & Cui, Q. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092791 · Cited by 116
Self-citationThe two faces of Cdk8, a positive/negative regulator of transcription
Nemet, J., Jelicic, B., Rubelj, I., & Sopta, M. (2014) · Biochimie · doi:10.1016/j.biochi.2013.10.004 · Cited by 115
Chen, Y.-J., Dominguez‐Brauer, C., Wang, Z., Asara, J. M., Costa, R. H., Tyner, A. L., Lau, L. F., & Raychaudhuri, P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.007997 · Cited by 111
miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer
Mathe, A., Scott, R. J., & Avery‐Kiejda, K. A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226090 · Cited by 111
Therapeutic targeting of transcriptional cyclin-dependent kinases
Galbraith, M. D., Bender, H., & Espinosa, J. M. (2018) · Transcription · doi:10.1080/21541264.2018.1539615 · Cited by 111
Nie, L., Wei, Y., Zhang, F., Hsu, Y.-H. E., Chan, L.-C., Xia, W., Ke, B., Zhu, C., Deng, R., Tang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13105-5 · Cited by 111
Self-citationNiu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 109
Re, M. D., Bertolini, I., Crucitta, S., Fontanelli, L., Rofi, E., Angelis, C. D., Diodati, L., Cavallero, D., Gianfilippo, G., Salvadori, B., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05365-y · Cited by 104
Li, B., Chonghaile, T. N., Fan, Y., Madden, S. F., Klinger, R. W., O’Connor, A. E., Walsh, L., O’Hurley, G., Udupi, G. M., Joseph, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2546 · Cited by 103
Spring, L. M., Bardia, A., & Modi, S. (2016) · PubMed · Cited by 102
Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Jin, J., Fang, H., Yang, F., Ji, W., Guan, N., Sun, Z., Shi, Y., Zhou, G., & Guan, X. (2018) · Neoplasia · doi:10.1016/j.neo.2018.03.003 · Cited by 101
Robinson, T., Liu, J. C., Vizeacoumar, F. S., Sun, T., MacLean, N., Egan, S. E., Schimmer, A. D., Datti, A., & Zacksenhaus, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078641 · Cited by 96
Resveratrol chemosensitizes adriamycin‐resistant breast cancer cells by modulating miR‐122‐5p
Zhang, W., Jiang, H., Chen, Y., & Ren, F. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28910 · Cited by 95
Park, M., Watanabe, S., Poon, V. Y., Ou, C.-Y., Jørgensen, E. M., & Shen, K. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.002 · Cited by 91
Shiraishi, Y., Fujimoto, A., Furuta, M., Tanaka, H., Chiba, K., Boroevich, K. A., Abe, T., Kawakami, Y., Ueno, M., Gotoh, K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114263 · Cited by 90
CDK Inhibitors: From the Bench to Clinical Trials
Rizzolio, F., Tuccinardi, T., Caligiuri, I., Lucchetti, C., & Giordano, A. (2010) · Current Drug Targets · doi:10.2174/138945010790711978 · Cited by 90
Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer
Broude, E. V., Győrffy, B., Chumanevich, A. A., Chen, M., McDermott, M. S. J., Shtutman, M. S., Catroppo, J. F., & Roninson, I. B. (2015) · Current Cancer Drug Targets · doi:10.2174/156800961508151001105814 · Cited by 90
Cretella, D., Fumarola, C., Bonelli, M. A., Alfieri, R. R., Monica, S. L., Digiacomo, G., Cavazzoni, A., Galetti, M., Generali, D., & Petronini, P. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-49484-4 · Cited by 85
Cell Cycle-dependent Regulation of the Forkhead Transcription Factor FOXK2 by CDK·Cyclin Complexes
Marais, A., Ji, Z., Child, E. S., Krause, E., Mann, D. J., & Sharrocks, A. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.154005 · Cited by 84
The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
Zhou, Y., Shen, J. K., Hornicek, F. J., Kan, Q., & Duan, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.8519 · Cited by 84
NavaneethaKrishnan, S., Rosales, J. L., & Lee, K. (2018) · Oncogene · doi:10.1038/s41388-017-0103-1 · Cited by 84
Ballinger, T. J., Meier, J. B., & Jansen, V. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00308 · Cited by 82
Zheng, P., Dong, L., Zhang, B., Dai, J., Zhang, Y., Wang, Y., & Qin, S. (2019) · Histochemistry and Cell Biology · doi:10.1007/s00418-019-01794-4 · Cited by 78
Jabbour-Leung, N. A., Chen, X., Bui, T. N., Jiang, Y., Yang, D., Vijayaraghavan, S., McArthur, M. J., Hunt, K. K., & Keyomarsi, K. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0519 · Cited by 76
Clemente‐Blanco, A., Sen, N., Mayán, M. D., Sacristán, M. P., Graham, B., Jarmuz, A., Giess, A. P., Webb, E., Gamé, L., Eick, D., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2365 · Cited by 75
Zhou, Y., Han, C., Li, D., Yu, Z., Li, F., Li, F., An, Q., Bai, H., Zhang, X., Duan, Z., et al. (2015) · Scientific Reports · doi:10.1038/srep10433 · Cited by 74
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F. M., Haider, S. A., Kriplani, D., Campbell, J., Mirza, H., Grigoriadis, A. E., Tutt, A. N. J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0760 · Cited by 72
Cheng, X., Tan, S., Duan, F., et al. (2019) · Breast Cancer · doi:10.1007/s12282-019-00980-5 · Cited by 70
Liu, D., You, P., Luo, Y., Yang, M., & Liu, Y. (2018) · Pharmacology · doi:10.1159/000489564 · Cited by 66
Sever-Chroneos, Z., Angus, S. P., Fribourg, A. F., Wan, H., Todorov, I., Knudsen, K. E., & Knudsen, E. S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.4032-4045.2001 · Cited by 65
Cyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and future
DiPippo, A. J., Patel, N. K., & Barnett, C. M. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1756 · Cited by 60
Liu, Q., Cao, Y., Zhou, P., Gui, S., Wu, X., Xia, Y., & Tu, J. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.042 · Cited by 60
Human CDK18 promotes replication stress signaling and genome stability
Barone, G., Staples, C. J., Ganesh, A., Patterson, K. W., Bryne, D. P., Myers, K. N., Patil, A. A., Eyers, C. E., Maslen, S., Skehel, J. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw615 · Cited by 59
Chen, X., Xu, D., Li, X., Zhang, J., Xu, W., Hou, J., Zhang, W., & Tang, J. (2019) · Journal of Cancer · doi:10.7150/jca.33079 · Cited by 56
miR-455 inhibits breast cancer cell proliferation through targeting CDK14
Wang, B., Zou, A., Ma, L., Chen, X., Wang, L., Zeng, X., & Tan, T. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.016 · Cited by 55
Xie, D., Song, H., Wu, T., Li, D., Hua, K., Xu, H., Zhao, B., Wu, C., Hu, J., Ji, C., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6741 · Cited by 55
Tolaney, S. M., Lin, N., Thornton, D., Klise, S. R., Costigan, T. M., Turner, P. K., & Anders, C. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1019 · Cited by 54
CDK4/6 inhibitors in breast cancer
Dukelow, T., Kishan, D., Khasraw, M., & Murphy, C. G. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000249 · Cited by 53
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Matutino, A. R. B., Amaro, C. P., & Verma, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918818346 · Cited by 52
Liu, L., Tian, Q., Liu, J., Zhou, Y., & Yong, H. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28536 · Cited by 51
The awakening of the CDK10/Cyclin M protein kinase
Guen, V. J., Gamble, C., Lees, J. A., & Colas, P. (2017) · Oncotarget · doi:10.18632/oncotarget.15024 · Cited by 49
Zhang, H., Zhao, B., Wang, X., Zhang, F., & Yu, W. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.063 · Cited by 49
Lanasa, M. C., Andritsos, L. A., Brown, J. R., Gabrilove, J. L., Caligaris‐Cappio, F., Ghia, P., Larson, R. A., Kipps, T. J., Leblond, V., Milligan, D. W., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.02.001 · Cited by 48
Ou-Yang, J., Huang, L.-H., & Sun, X. (2016) · Gynecologic and Obstetric Investigation · doi:10.1159/000447632 · Cited by 45
Cdc14b regulates mammalian RNA polymerase II and represses cell cycle transcription
Guillamot, M., Manchado, E., Chiesa, M., Goméz-López, G., Pisano, D. G., Sacristán, M. P., & Malumbres, M. (2011) · Scientific Reports · doi:10.1038/srep00189 · Cited by 42
Messer, J. A., Ekinci, E., Patel, T. A., & Teh, B. S. (2019) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2019.03.001 · Cited by 42
Jeong, C. H., Ryu, H., Kim, D. H., Cheng, W. N., Yoon, J. E., Kang, S., & Han, S. G. (2019) · Antioxidants · doi:10.3390/antiox8110553 · Cited by 42
Chaput, D., Kirouac, L., Stevens, S. M., & Padmanabhan, J. (2016) · Oncotarget · doi:10.18632/oncotarget.7380 · Cited by 40
Activated kinase screening identifies the IKBKE oncogene as a positive regulator of autophagy
Leonardi, M., Perna, E., Tronnolone, S., Colecchia, D., & Chiariello, M. (2018) · Autophagy · doi:10.1080/15548627.2018.1517855 · Cited by 40
Zhang, X., Zhao, Y., Wang, C., Ju, H., Liu, W., Zhang, X., Miao, S., Wang, L., Sun, Q., & Song, W. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0267-5 · Cited by 38
El‐Hafeez, A. A. A., Khalifa, H. O., Mahdy, E. A. M., Sharma, V., Hosoi, T., Ghosh, P., Ozawa, K., Montano, M. M., Fujimura, T., Ibrahim, A. R. N., et al. (2019) · Pharmacological Reports · doi:10.1016/j.pharep.2019.01.001 · Cited by 38
PCTAIRE1/PCTK1/CDK16: a new oncotarget?
Yanagi, T., & Matsuzawa, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1006539 · Cited by 36
Genetic expression profiles and chromosomal alterations in sporadic breast cancer in Mexican women
Valladares, A., García-Hernández, N., Gómez, F. S., Curiel‐Quesada, E., Madrigal‐Bujaidar, E., Vergara, M. D., Martínez, M. S., & Arenas-Aranda, D. J. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.06.002 · Cited by 36
Imawari, Y., Mimoto, R., Hirooka, S., Morikawa, T., Takeyama, H., & Yoshida, K. (2017) · Cancer Science · doi:10.1111/cas.13459 · Cited by 36
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
Giannone, G., Tuninetti, V., Ghisoni, E., Genta, S., Scotto, G., Mittica, G., & Valabrega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092353 · Cited by 35
Mazumdar, A., Tahaney, W. M., Bollu, L. R., Poage, G. M., Hill, J. L., Zhang, Y., Mills, G. B., & Brown, P. H. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0118-6 · Cited by 34
Kim, D., Wang, C. Y., Hu, R., Lee, J. Y., Luu, T.-T.-T., Park, H.-J., & Lee, S. K. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00720 · Cited by 34
Lee, S., Lee, M., Lee, K.-R., Lee, E., & Lee, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051147 · Cited by 28
Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo
Elango, R., Vishnubalaji, R., Manikandan, M., Binhamdan, S., Siyal, A., Alshawakir, Y. A., Alfayez, M. A., Aldahmash, A. M., & Alajez, N. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-50140-0 · Cited by 26
The C-Terminal Domain of Rpb1 Functions on Other RNA Polymerase II Subunits
Suh, H., Hazelbaker, D. Z., Soares, L. M., & Buratowski, S. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.015 · Cited by 23
Song, W., Wu, S., Wu, Q., Zhou, L., Yu, L., Zhu, B., & Gong, X. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28685 · Cited by 23
PA28α/β Promote Breast Cancer Cell Invasion and Metastasis via Down-Regulation of CDK15
Li, S., Dai, X., Gong, K., Song, K., Tai, F., & Shi, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01283 · Cited by 22
van der Noord, V. E., McLaughlin, R. P., Smid, M., Foekens, J. A., Martens, J. W. M., Zhang, Y.-H., & van de Water, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-49809-3 · Cited by 21
Hasanpourghadi, M., Pandurangan, A. K., Karthikeyan, C., Trivedi, P., & Mustafa, M. R. (2017) · Oncotarget · doi:10.18632/oncotarget.16263 · Cited by 20
Bevara, G. B., Kumar, A. D. N., Koteshwaramma, K. L., Badana, A. K., Kumari, S., & Malla, R. R. (2018) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_51_16 · Cited by 19
Barone, G., Arora, A., Ganesh, A. N., Abdel-Fatah, T. M. A., Moseley, P. M., Ali, R., Chan, S. Y. T., Savva, C., Schiavone, K., Carmell, N., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25686 · Cited by 17
A clinical evaluation of treatments that target cell cycle machinery in breast cancer
Fedele, P., Sanna, V., Fancellu, A., & Cinieri, S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1672659 · Cited by 16
Chen, J., Ko, J., Kim, J. T., Cho, J. S., Qiu, S., Kim, G.-D., Auh, J., & Lee, H. J. (2019) · Food & Function · doi:10.1039/c9fo00009g · Cited by 14
Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
Spring, L. M., & Bardia, A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0463 · Cited by 11
Keeping CDK18 in balance to prevent DNA replication stress in breast cancer
Braams, E., & D’Angiolella, V. (2018) · Oncotarget · doi:10.18632/oncotarget.26517 · Cited by 6
Cited by
Braal, C. L., Jongbloed, E. M., Wilting, S. M., Mathijssen, R. H. J., Koolen, S. L. W., & Jager, A. (2021) · Drugs · doi:10.1007/s40265-020-01461-2 · Cited by 438
Pal-Ghosh, R., Xue, D., Warburton, R., Hill, N., Polgar, P., & Wilson, J. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136943 · Cited by 22
Metadata
- Authors
- Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-03-13
- Volume
- 21
- Issue
- 6
- Pages
- 1960
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3010714596
- Cited by
- 618
- References
- 168
- FWCI
- 34.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.